Research

Hormonal

Therapeutic silencing of miR-33 using antisense oligonucleotides increases plasma HDL cholesterol levels by targeting cholesterol efflux transporters ABCA1 and ABCG1.

While direct 'miR-33 silencing' is not a current consumer supplement, this research highlights why some individuals struggle with HDL levels despite diet. Future therapies targeting this pathway may offer treatment for dyslipidemia, but current lifestyle interventions (diet/exercise) remain the primary method to influence these genetic pathways naturally.

ModerateSupportsMEDIUM confidence
Silencing of miR-33 in vivo increased plasma HDL levels by targeting adenosine triphosphate-binding cassette transporter A1 (ABCA1) and adenosine triphosphate-binding cassette transporter G1 (ABCG1), thereby attenuating cholesterol efflux to apolipoprotein A1 (ApoA1) or reducing cholesterol efflux to nascent HDL.
Zhihong Yang et al. · Acta Pharmaceutica Sinica B · 2015

Why this rating

The paper is a review summarizing multiple studies (in vivo mouse models, non-human primates), but does not present a single primary clinical trial itself.

Source

Emerging role of microRNAs in lipid metabolism

Zhihong Yang et al. · Acta Pharmaceutica Sinica B · 2015

DOI 10.1016/j.apsb.2015.01.002

narrative_reviewCited 173×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →